Nivalis Therapeutics Announces Pricing of Its Initial Public Offering

BOULDER, Colo., June 16, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc., (Nasdaq:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, announced today the pricing of its initial public offering of 5.5 million shares of its common stock at a price to the public of $14.00 per share, before underwriting discounts and commissions.

In addition, Nivalis has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of the common stock in this offering are being sold by Nivalis. Nivalis' shares are expected to begin trading on The NASDAQ Global Market on June 17, 2015 under the ticker symbol "NVLS." This offering is expected to close on June 22, 2015, subject to customary closing conditions.

Cowen and Company and Stifel are acting as joint lead book-running managers for the offering. Baird and H.C. Wainwright & Co. are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 16, 2015. The offering is being made only by means of a prospectus. Copies of the final prospectus related to the offering, when available, may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attn: Syndicate, by telephone at (415) 364-2720 or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of small molecule therapeutics for patients with cystic fibrosis. In addition to developing innovative solutions that extend and improve the lives of people with cystic fibrosis, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for patients with other diseases.

CONTACT: Investor Relations Contact John Graziano 1-646-378-2942 Media Contact Lindsay Rocco 1-862-596-1304 lrocco@elixirhealthpr.comSource: Nivalis Therapeutics